Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2025 | $18.00 | Buy | Truist |
| 10/16/2024 | $26.00 | Outperform | Oppenheimer |
| 10/3/2024 | $22.00 | Outperform | Wedbush |
| 10/2/2024 | $15.00 | Buy | H.C. Wainwright |
| 9/4/2024 | $16.00 | Outperform | Robert W. Baird |
| 4/3/2024 | $25.00 | Outperform | Leerink Partners |
| 11/17/2023 | $4.50 | Neutral → Buy | Citigroup |
| 10/19/2022 | $12.00 | Buy | Guggenheim |
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)Consistent directional improvement across 4 key clinical outcomes (mFARS, FARS-ADL, 9-HPT, MFIS) observed after 1 year of nomlabofusp treatment could suggest potential for clinical benefit relative to a worsening in a FACOMS natural history st
BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss updates for the Company's nomlabofusp clinical development program including data from the ongoing long-term open label study for the treatment of Friedreich's ataxia on Monday, September 29, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, September 29, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (do
Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp clinical studies are currently screening and enrolling in the open label study; planning to enroll children (2 to 11 years of age) directly into the open label studyFDA recommended that the safety database include at least 30 participants with continuous study drug exposure for 6 months, and a subset of at least 10 participants for 1-year; large majority of safety data should be from participants receiving 50 mg nomlabofuspPublished two peer-r
Truist initiated coverage of Larimar Therapeutics with a rating of Buy and set a new price target of $18.00
Oppenheimer initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $26.00
Wedbush initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $22.00
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
10-Q - Larimar Therapeutics, Inc. (0001374690) (Filer)
SCHEDULE 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company's Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in regulatory and clinical strategy. "Dr. Sherman is a pharmaceutical industry veteran who brings decades of leadership experience in global regulatory and clinical strategy to our Board of Directors.
Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 dataTop-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Cash, cash equivalents and marketable securities of $104.2 million as of June 30, 2023, provides projected cash runway into Q4 2024 BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Lari
BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell "Rusty" Clayton, DO, as Chief Medical Officer ("CMO"), effective today. Dr. Clayton succeeds former CMO Nancy M. Ruiz, MD, who is retiring and will provide consulting support to the Company as needed. "We are delighted to welcome Dr. Clayton in his new role as CMO as we further expand our clinical development of CTI-1601. Rusty has been one of our closest advisors for the last 5 years, has attended every meeting between Larimar and the FDA, in
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)Consistent directional improvement across 4 key clinical outcomes (mFARS, FARS-ADL, 9-HPT, MFIS) observed after 1 year of nomlabofusp treatment could suggest potential for clinical benefit relative to a worsening in a FACOMS natural history st
BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss updates for the Company's nomlabofusp clinical development program including data from the ongoing long-term open label study for the treatment of Friedreich's ataxia on Monday, September 29, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, September 29, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (do
Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLAWritten FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated approval planned in the second quarter of 2026 to allow for inclusion of the recommended safety data for adults and childrenOLE data expected in September 2025 from 30-40 participants who received at least one dose of nomlabofusp; data will include participants on the 50 mg doseAdolescent PK run-in data e